ArticleParasitology research2004
The use of CpG as an adjuvant to Toxoplasma gondii vaccination.
Article in Parasitology research, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 15 citations in OpenAlex.
- Evaluation of CpG-ODN-AdjuvantedPharmaceutics · 2020Article
- Evaluation of Immunogenic Effect ofAdvanced pharmaceutical bulletin · 2019Article
- Rhoptry antigens asClinical and experimental vaccine research · 2019Review
- The effect of chitosan nanospheres on the immunogenicity of Toxoplasma lysate vaccine in mice.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2016Article
- A comparative study between excretory/secretory and autoclaved vaccines against RH strain of Toxoplasma gondii in murine models.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2015Article
- Protective immune response in BALB/c mice induced by DNA vaccine of the ROP8 gene of Toxoplasma gondii.The American journal of tropical medicine and hygiene · 2013Article
- Toxoplasma rhoptries: unique secretory organelles and source of promising vaccine proteins for immunoprevention of toxoplasmosis.Journal of biomedicine & biotechnology · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Unmethylated CpG dinucleotides have been found to stimulate general immune responses in mammals. CpG motifs have further been shown to be potent adjuvants when used in conjunction with vaccines for viral and bacterial organisms. It was necessary to determine whether these CpG motifs will also enhance immune responses in parasitic diseases. We therefore decided to test the effect of CpG adjuventation on immunization with a temperature-sensitive mutant (ts4) strain of Toxoplasma gondii. Mice were divided into groups receiving either ts4 only, CpG only, ts4 with CpG, or untreated controls. Mice were challenged with a lethal dose of T. gondii (RH strain) tachyzoites 28 days after vaccination. There were significant differences observed between the ts4-only group and the other three groups with regards to antibody isotype and survival, with the former group surviving lethal challenge. CpG adjuventation appeared to not enhance survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.